CD7

Summary

CD7 (CD7 molecule, HGNC:1695) is a protein-coding gene on chromosome 17q25.3, encoding T-cell antigen CD7 (P09564). Transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors.

This gene encodes a transmembrane protein which is a member of the immunoglobulin superfamily. This protein is found on thymocytes and mature T cells. It plays an essential role in T-cell interactions and also in T-cell/B-cell interaction during early lymphoid development.

Source: NCBI Gene 924 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 57 total
• MANE Select transcript: NM_006137

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1695
Approved symbol	CD7
Name	CD7 molecule
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	GP40, LEU-9, TP41, Tp40
Ensembl gene	ENSG00000173762
Ensembl biotype	protein_coding
OMIM	186820
Entrez	924

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 3 nonsense_mediated_decay, 1 retained_intron

ENST00000312648, ENST00000578509, ENST00000581434, ENST00000581744, ENST00000582480, ENST00000583376, ENST00000584284, ENST00000850579

RefSeq mRNA: 1 — MANE Select: NM_006137 NM_006137

CCDS: CCDS11807

Canonical transcript exons

ENST00000312648 — 4 exons

Exon	Start	End
ENSE00001190456	82316667	82316981
ENSE00001244932	82316195	82316409
ENSE00001298774	82314873	82315431
ENSE00004282194	82317414	82317608

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 98.38.

FANTOM5 (CAGE): breadth broad, TPM avg 17.5677 / max 885.5485, expressed in 520 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
168966	8.6616	319
168967	6.9149	414
168965	1.9912	171

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	98.38	gold quality
blood	UBERON:0000178	91.59	gold quality
spleen	UBERON:0002106	91.27	gold quality
vermiform appendix	UBERON:0001154	88.93	gold quality
lymph node	UBERON:0000029	88.72	gold quality
thymus	UBERON:0002370	84.75	gold quality
caecum	UBERON:0001153	84.26	gold quality
mucosa of transverse colon	UBERON:0004991	84.04	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.70	gold quality
small intestine	UBERON:0002108	80.75	gold quality
upper lobe of left lung	UBERON:0008952	79.93	gold quality
bone marrow cell	CL:0002092	79.01	gold quality
upper lobe of lung	UBERON:0008948	78.42	gold quality
leukocyte	CL:0000738	77.92	gold quality
right lung	UBERON:0002167	77.73	gold quality
omental fat pad	UBERON:0010414	77.71	gold quality
peritoneum	UBERON:0002358	77.67	gold quality
right lobe of liver	UBERON:0001114	76.78	gold quality
adipose tissue of abdominal region	UBERON:0007808	76.63	gold quality
decidua	UBERON:0002450	76.62	silver quality
bone marrow	UBERON:0002371	76.55	gold quality
mononuclear cell	CL:0000842	76.08	gold quality
duodenum	UBERON:0002114	76.03	gold quality
monocyte	CL:0000576	75.75	gold quality
transverse colon	UBERON:0001157	75.11	gold quality
jejunal mucosa	UBERON:0000399	75.09	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	75.02	gold quality
body of stomach	UBERON:0001161	74.67	gold quality
triceps brachii	UBERON:0001509	74.11	gold quality
gluteal muscle	UBERON:0002000	74.08	gold quality

Single-cell (SCXA)

Detected in 37 experiment(s), a significant marker in 34.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	3293.04
E-MTAB-6701	yes	3175.83
E-MTAB-6653	yes	3022.98
E-CURD-122	yes	2711.57
E-CURD-77	yes	2342.09
E-MTAB-8142	yes	2295.46
E-MTAB-10553	yes	2115.59
E-CURD-88	yes	2066.46
E-GEOD-125970	yes	2063.62
E-MTAB-6308	yes	1919.19
E-MTAB-9906	yes	1796.55
E-HCAD-4	yes	1790.78
E-HCAD-1	yes	1711.17
E-HCAD-36	yes	1626.48
E-HCAD-32	yes	1621.29

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, SP1, TAL1, TCF3, TWIST2

miRNA regulators (miRDB)

32 targeting CD7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-7156-3P	98.25	67.66	859
HSA-MIR-4288	97.11	67.23	1636
HSA-MIR-212-5P	96.83	67.43	950
HSA-MIR-5194	96.77	63.91	1021
HSA-MIR-4467	96.51	64.44	69
HSA-MIR-6738-5P	96.33	63.61	815
HSA-MIR-541-3P	96.07	66.11	1271
HSA-MIR-654-5P	96.07	66.18	1280
HSA-MIR-2861	95.24	65.47	1056

Literature-anchored findings (GeneRIF, showing 29)

• CD7 expression in hematopoitic cells denotes commitment to B-cell and natural killer cells lineages. (PMID:12393702)
• Association of T cell antigen CD7 with type II phosphatidylinositol-4 kinase, a key component in pathways of inositol phosphate turnover. (PMID:12594831)
• a novel fusion protein, designated scFvCD7:sFasL is designed to have leukemia-restricted activity. (PMID:16332967)
• Patients expressing CD7 had significant shorter disease free (DFS) and post-remission survivals (PRS) than patients without CD7 (DFS of 12 months versus 42 months, P=0.005; PRS of 15 months versus 33 months, P=0.013). (PMID:16837044)
• CD7 antigen notably expresses in lung microvascular endothelial cells (LME) and that it acts as an Fc receptor for IgM in LME cells. (PMID:16990185)
• HTLV-IInfected cells acquired a profound decrease of intracellular calcium levels in response to ionomycin, timely correlated with decreased CD7 expression (PMID:17287851)
• differential levels of CD7 identify the progressive stages of lineage commitment in human thymus, initiated from a primitive CD7(-) lympho-myeloid thymic progenitor (PMID:17959857)
• close association of aberrant CD7 expression and FLT3/ITD mutation in the myeloblasts of FLT3/ITD+ acute myeloid leukemia suggests that FLT3/ITD- mediated leukemic transformation occurs in the more early stage of myeloid progenitor cells (PMID:18343790)
• The CD7 expression in CD4(+) T cells discriminates between HL and reactive LAD, suggesting that this could be a useful and practical adjunctive tool in the diagnosis of Hodgkin lymphoma. (PMID:18956470)
• by down-regulating CD7, ATLL cells could have escaped Gal-3-induced apoptosis to run a more aggressive clinical course (PMID:19207946)
• the galectin-1 glycoprotein receptor CD7 maybe a novel target for GdA on T cells. (PMID:19683346)
• low expression in T-cell lymphomas due to Twist2-mediated suppression of promoter activity; enhanced by histone deacetylase inhibitors (PMID:19937140)
• CD7 loss in aggressive natural killer-cell leukemia; a useful diagnostic marker (PMID:20046078)
• These findings indicate a link between epigenetic modifications and CD7 expression in primitive chronic myeloid leukemia cells. (PMID:20175919)
• epigenetic down-regulation of CD7 is associated with acute myeloid leukemia. (PMID:20398252)
• CD7 is present on monocytes and tumor macrophages and its ligand, SECTM1, is frequently expressed in corresponding melanoma tissues (PMID:24157461)
• SECTM1 secreted from bone marrow stromal cells may interact with CD7 to influence GM-CSF expression in leukemic cells. (PMID:24211252)
• We showed that the CADM1 versus CD7 plot is capable of discriminating clonally expanding HTLV-I-infected cells in indolent and acute-type T-cell leukemia-lymphomas and in asymptomatic carriers (PMID:24727323)
• Data show that CD7 promotes extramedullary involvement of the B-ALL line Tanoue in an integrin beta2-dependent manner. (PMID:24920488)
• in acute myeloid leukemia patients the association of CD7 positivity and FLT3 positivity was found to be significant (PMID:25679063)
• Dysfunctional immunoregulation in liver allograft rejection patients can be partly attributed to reduced regulatory T-cell Gal1 expression and reduced responder T-cell CD7 expression. (PMID:29463785)
• FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression. (PMID:32460405)
• [Expression of CD7 and its correlation with prognosis in patients with NK/T-cell lymphoma]. (PMID:33333695)
• CD2 and CD7 are sensitive flow cytometry screening markers for T-lineage acute leukemia(s): a study of 465 acute leukemia cases. (PMID:34019867)
• Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations. (PMID:34034609)
• Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission. (PMID:34176091)
• T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. (PMID:35332132)
• Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. (PMID:37314354)
• CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion. (PMID:38123919)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-165d12.4	ENSDARG00000079353
danio_rerio	si:ch211-188c18.1	ENSDARG00000101654
danio_rerio	si:rp71-81e14.2	ENSDARG00000103077
mus_musculus	Cd7	ENSMUSG00000025163
rattus_norvegicus	Cd7	ENSRNOG00000036674

Protein

Protein identifiers

T-cell antigen CD7 — P09564 (reviewed: P09564)

Alternative names: GP40, T-cell leukemia antigen, T-cell surface antigen Leu-9, TP41

All UniProt accessions (7): P09564, J3QLC7, J3QLM0, J3QRF1, J3QS65, J3QS78, Q29VG3

UniProt curated annotations — full annotation on UniProt →

Function. Transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. Plays a costimulatory role in T-cell activation upon binding to its ligand K12/SECTM1. In turn, mediates the production of cytokines such as IL-2. On resting NK-cells, CD7 activation results in a significant induction of interferon-gamma levels.

Subunit / interactions. Interacts with SECTM1.

Subcellular location. Membrane.

Tissue specificity. Expressed on T-cells and natural killer (NK) cells and their precursors.

RefSeq proteins (1): NP_006128* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR039090	CD7	Family

Pfam: PF07686

UniProt features (18 total): repeat 4, region of interest 2, glycosylation site 2, disulfide bond 2, topological domain 2, signal peptide 1, chain 1, lipid moiety-binding region 1, sequence variant 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
12HP	X-RAY DIFFRACTION	2
12NP	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P09564-F1	77.51	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 198

Disulfide bonds (2): 35–142, 48–114

Glycosylation sites (2): 45, 96

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 247 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GNF2_ZAP70, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, GOBP_CYTOKINE_PRODUCTION, GOBP_POSITIVE_REGULATION_OF_T_CELL_CYTOKINE_PRODUCTION, GOBP_REGULATION_OF_LYMPHOCYTE_MEDIATED_IMMUNITY, GNF2_IL2RB, GOBP_ADAPTIVE_IMMUNE_RESPONSE, SANSOM_APC_TARGETS_DN

GO Biological Process (7): adaptive immune response (GO:0002250), positive regulation of T cell cytokine production (GO:0002726), immune response (GO:0006955), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), T cell activation (GO:0042110), immune system process (GO:0002376), interleukin-2-mediated signaling pathway (GO:0038110)

GO Molecular Function (3): transmembrane signaling receptor activity (GO:0004888), signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	1
T cell cytokine production	1
positive regulation of T cell mediated immunity	1
positive regulation of cytokine production involved in immune response	1
regulation of T cell cytokine production	1
immune system process	1
response to stimulus	1
enzyme-linked receptor protein signaling pathway	1
lymphocyte activation	1
biological_process	1
cytokine-mediated signaling pathway	1
cellular response to interleukin-2	1
signaling receptor activity	1
molecular transducer activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1432 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD7	CD2	P06729	967
CD7	ANPEP	P15144	963
CD7	CD5	P06127	956
CD7	SECTM1	Q8WVN6	951
CD7	FCGR3B	O75015	920
CD7	NCAM1	P13591	898
CD7	CD4	P01730	891
CD7	CD33	P20138	870
CD7	FCGR3A	P08637	867
CD7	FUT4	P22083	865
CD7	CD38	P28907	851
CD7	MME	P08473	840
CD7	ITGAM	P11215	830
CD7	APCDD1	Q8J025	825
CD7	PTPRC	P08575	819

IntAct

12 interactions, top by confidence:

A	B	Type	Score
CD7	PTRH2	psi-mi:“MI:0915”(physical association)	0.620
SEC22A	CD7	psi-mi:“MI:0915”(physical association)	0.560
CD7	SEC22A	psi-mi:“MI:0915”(physical association)	0.560
CD7	MYADM	psi-mi:“MI:0914”(association)	0.530
PIK3R1	CD7	psi-mi:“MI:0914”(association)	0.530
CD7	NFKBIA	psi-mi:“MI:0915”(physical association)	0.370
CPTP	CD7	psi-mi:“MI:0915”(physical association)	0.370
CD7	PIK3R2	psi-mi:“MI:0914”(association)	0.350
PIK3R1	CD7	psi-mi:“MI:0914”(association)	0.350
CD7		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (24): PTRH2 (Affinity Capture-MS), MYADM (Affinity Capture-MS), CD7 (Two-hybrid), CD7 (Reconstituted Complex), PIK3R1 (Affinity Capture-Western), PI4K2A (Affinity Capture-Western), PTRH2 (Affinity Capture-MS), CD7 (Affinity Capture-Western), PIK3CB (Affinity Capture-MS), PIK3R1 (Affinity Capture-MS), SLC30A9 (Affinity Capture-MS), SECTM1 (Affinity Capture-MS), TYW1 (Affinity Capture-MS), RFT1 (Affinity Capture-MS), PIGS (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GW64, A0A5F4BST2, A0PJX4, A8MVS5, A8MWV9, B0FP48, E5RIL1, E9PGG2, O14836, O60320, O95998, P09564, Q01113, Q01114, Q13477, Q2KI80, Q2T9R2, Q3TS39, Q3UPR0, Q3URD2, Q4V9L6, Q5FVJ4, Q5M869, Q6A044, Q6UWJ8, Q75VT8, Q864V4, Q8BRJ3, Q8BX43, Q8C503, Q8IVY1, Q8K5A9, Q8N112, Q8NC24, Q8NDY8, Q8QZT4, Q8R138, Q969Z4, Q9BUF7, Q9CQM1

Diamond homologs: P01635, P01636, P01670, P01671, P01674, P01685, P01696, P04945, P09564, P0C673, P50283, Q08DK1, Q5DX21, Q5U2P2, A2AJ76, D3YXG0, P78310, Q08E08, Q29RR6, Q4KLY3, Q5R764, Q6AYD4, Q6WRH9, Q6WRI0, Q86XK7, Q8K1G0, Q8NDA2, Q8R373, Q90W79, Q90Y50, Q91664, Q925F2, Q92626, Q96IQ7, Q96JA1, Q96RW7, Q99795, Q9D2J4, Q9H6B4, Q9JMB8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

509 predictions. Top by Δscore:

Variant	Effect	Δscore
17:82316662:CCTA:C	donor_loss	1.0000
17:82316663:CTAC:C	donor_loss	1.0000
17:82316664:TA:T	donor_loss	1.0000
17:82316665:A:AC	donor_gain	1.0000
17:82316666:C:CC	donor_gain	1.0000
17:82316666:C:CG	donor_loss	1.0000
17:82316666:CCTG:C	donor_gain	1.0000
17:82316668:TGTC:T	donor_gain	1.0000
17:82316708:T:TA	donor_gain	1.0000
17:82315431:TCTGA:T	acceptor_loss	0.9900
17:82315432:C:A	acceptor_loss	0.9900
17:82316667:CTGT:C	donor_gain	0.9900
17:82315432:C:CC	acceptor_gain	0.9800
17:82316250:A:AC	donor_gain	0.9700
17:82316666:CCTGT:C	donor_gain	0.9700
17:82316702:TTG:T	donor_gain	0.9700
17:82317017:C:CT	acceptor_gain	0.9700
17:82315429:TAT:T	acceptor_gain	0.9600
17:82316056:TCC:T	donor_gain	0.9600
17:82316410:C:CC	acceptor_gain	0.9600
17:82315427:TTTAT:T	acceptor_gain	0.9400
17:82316703:TG:T	donor_gain	0.9400
17:82316408:CTCTG:C	acceptor_loss	0.9300
17:82316409:TCT:T	acceptor_loss	0.9300
17:82316410:CT:C	acceptor_loss	0.9300
17:82316411:T:A	acceptor_loss	0.9300
17:82316190:CTGA:C	donor_loss	0.9200
17:82316191:TGA:T	donor_loss	0.9200
17:82316192:GACC:G	donor_loss	0.9200
17:82316193:ACCT:A	donor_loss	0.9200

AlphaMissense

1506 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:82316768:A:T	I99N	0.997
17:82316774:A:G	L97P	0.997
17:82316723:C:G	C114S	0.996
17:82316724:A:G	C114R	0.996
17:82316724:A:T	C114S	0.996
17:82316730:A:C	Y112D	0.996
17:82316741:T:A	D108V	0.996
17:82316768:A:C	I99S	0.996
17:82316768:A:G	I99T	0.996
17:82316812:G:C	F84L	0.996
17:82316812:G:T	F84L	0.996
17:82316813:A:C	F84C	0.996
17:82316814:A:G	F84L	0.996
17:82316794:G:C	F90L	0.995
17:82316794:G:T	F90L	0.995
17:82316796:A:G	F90L	0.995
17:82316813:A:G	F84S	0.995
17:82316888:A:G	L59P	0.995
17:82316927:A:G	I46T	0.995
17:82316729:T:C	Y112C	0.994
17:82316921:C:G	C48S	0.994
17:82316922:A:G	C48R	0.994
17:82316922:A:T	C48S	0.994
17:82316723:C:T	C114Y	0.993
17:82316927:A:C	I46S	0.993
17:82316730:A:G	Y112H	0.992
17:82316741:T:C	D108G	0.992
17:82316898:C:A	G56W	0.992
17:82316678:A:T	V129D	0.991
17:82316722:G:C	C114W	0.991

dbSNP variants (sampled 300 via entrez): RS1000433348 (17:82315242 G>A), RS1000813476 (17:82315703 C>G), RS1001155664 (17:82315610 G>A), RS1002051385 (17:82317200 TCCCAAAGCAGCGG>T), RS1002579673 (17:82317035 C>A,T), RS1004691438 (17:82318535 G>A,T), RS1004890602 (17:82314631 C>T), RS1005286223 (17:82314916 C>T), RS1006306903 (17:82315863 G>A,T), RS1006448402 (17:82315643 A>G,T), RS1006606224 (17:82315218 C>T), RS1007725995 (17:82316278 A>C), RS1008396972 (17:82319588 G>C), RS1008429557 (17:82318366 T>C,G), RS1008766667 (17:82317296 C>A,T)

Disease associations

OMIM: gene MIM:186820 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_1657	Blood protein levels	1.000000e-61

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tetrachlorodibenzodioxin	increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
bisphenol A	affects expression	1
(+)-JQ1 compound	decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Benzene	increases expression	1
Benzo(a)pyrene	increases expression	1
Calcitriol	increases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Quercetin	increases expression	1
Smoke	increases expression	1
Testosterone	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	increases expression	1
Valproic Acid	increases methylation	1
S-Nitrosoglutathione	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8D6	Abcam HCT 116 CD7 KO	Cancer cell line	Male
CVCL_B9FD	Abcam A-549 CD7 KO	Cancer cell line	Male
CVCL_D2EB	Abcam MCF-7 CD7 KO	Cancer cell line	Female
CVCL_E8IV	Jurkat-NFAT-Luc2-CD7-KO-3A4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.